Perspectives in melanoma: meeting report from the “Melanoma Bridge” (December 5th–7th, 2019, Naples, Italy)

The melanoma treatment landscape changed in 2011 with the approval of the first anti-cytotoxic T-lymphocyte-associated protein (CTLA)-4 checkpoint inhibitor and of the first BRAF-targeted monoclonal antibody, both of which significantly improved overall survival (OS). Since then, improved understand...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Transl Med
Päätekijät: Ascierto, Paolo A., Puzanov, Igor, Agarwala, Sanjiv S., Blank, Christian, Carvajal, Richard D., Demaria, Sandra, Dummer, Reinhard, Ernstoff, Marc, Ferrone, Soldano, Fox, Bernard A., Gajewski, Thomas F., Garbe, Claus, Hwu, Patrick, Lo, Roger S., Long, Georgina V., Luke, Jason J., Osman, Iman, Postow, Michael A., Sullivan, Ryan J., Taube, Janis M., Trinchieri, Giorgio, Zarour, Hassane M., Caracò, Corrado, Thurin, Magdalena
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2020
Aiheet:
Meeting Report
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7487701/
https://ncbi.nlm.nih.gov/pubmed/32894202
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-020-02482-x
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia